Aldeyra Therapeutics, Inc.
ALDX
$1.51
-$0.03-1.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.44M | 7.74M | 9.60M | 9.19M | 10.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.07M | 28.38M | 35.27M | 45.18M | 53.31M |
| Operating Income | -24.07M | -28.38M | -35.27M | -45.18M | -53.31M |
| Income Before Tax | -23.05M | -27.37M | -33.85M | -43.19M | -50.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.05 | -27.37 | -33.85 | -43.19 | -50.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.05M | -27.37M | -33.85M | -43.19M | -50.62M |
| EBIT | -24.07M | -28.38M | -35.27M | -45.18M | -53.31M |
| EBITDA | -23.80M | -28.13M | -35.01M | -44.92M | -53.06M |
| EPS Basic | -0.38 | -0.46 | -0.56 | -0.72 | -0.85 |
| Normalized Basic EPS | -0.24 | -0.28 | -0.35 | -0.45 | -0.53 |
| EPS Diluted | -0.38 | -0.46 | -0.56 | -0.72 | -0.85 |
| Normalized Diluted EPS | -0.24 | -0.28 | -0.35 | -0.45 | -0.53 |
| Average Basic Shares Outstanding | 240.93M | 240.66M | 240.22M | 239.64M | 239.04M |
| Average Diluted Shares Outstanding | 240.93M | 240.66M | 240.22M | 239.64M | 239.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |